BACKGROUND: Technical limitations in the sensitivity of commercial genotyping methods may prevent clinicians from determining whether drug-resistant human immunodeficiency virus type 1 (HIV-1) is present in patients with low-level viremia. We performed ultrasensitive HIV-1 genotyping for patients with persistent plasma virus loads of 50-400 copies/mL to better define the prevalence of drug resistance and the most common resistance mutations during persistently detectable low-level viremia. METHODS: Genotyping of HIV-1 was performed with an ultrasensitive clonal genotyping method. RESULTS: We studied 21 patients who had persistent, detectable, low-level viremia for a median of 11 months. Nine (43%) of 21 patients had HIV-1 isolates with significant resistance mutations. The most common mutations were M184V, K65R, and M41L/T215Y. CONCLUSIONS: The finding that clinically significant resistance mutations were present in some but not all patients with persistent viremia (range, 50-400 copies/mL) highlights the need to improve the sensitivity of current clinical assays for detection of drug resistance.
BACKGROUND: Technical limitations in the sensitivity of commercial genotyping methods may prevent clinicians from determining whether drug-resistant human immunodeficiency virus type 1 (HIV-1) is present in patients with low-level viremia. We performed ultrasensitive HIV-1 genotyping for patients with persistent plasma virus loads of 50-400 copies/mL to better define the prevalence of drug resistance and the most common resistance mutations during persistently detectable low-level viremia. METHODS: Genotyping of HIV-1 was performed with an ultrasensitive clonal genotyping method. RESULTS: We studied 21 patients who had persistent, detectable, low-level viremia for a median of 11 months. Nine (43%) of 21 patients had HIV-1 isolates with significant resistance mutations. The most common mutations were M184V, K65R, and M41L/T215Y. CONCLUSIONS: The finding that clinically significant resistance mutations were present in some but not all patients with persistent viremia (range, 50-400 copies/mL) highlights the need to improve the sensitivity of current clinical assays for detection of drug resistance.
Authors: Michael R Jordan; Julie Winsett; Aileen Tiro; Vuth Bau; Rony S Berbara; Christopher Rowley; Nobel Bellosillo; Christine Wanke; Eoin P Coakley Journal: World J AIDS Date: 2013-06
Authors: Jonathan Z Li; Sebastien Gallien; Tri D Do; Jeffrey N Martin; Steven Deeks; Daniel R Kuritzkes; Hiroyu Hatano Journal: Antimicrob Agents Chemother Date: 2012-08-13 Impact factor: 5.191
Authors: Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna Journal: AIDS Date: 2014-05-15 Impact factor: 4.177